Featured

Status

All Statuses
  • Completed9

Health Topics

Any Category
Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Lymphoma
Clear Filters

Search Clinical Trials

9 Results
Completed
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells …
Baylor Role: Lead Sponsor
Completed
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults …
Baylor Role: Collaborator
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role: Lead Sponsor
Completed
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
First, we will search our cell bank to see if there is a CTL line that is a match with the subject and his/her donor. This matching is done using …
Baylor Role: Lead Sponsor
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role: Collaborator
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role: Lead Sponsor
Completed
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
ALASCER (Part 1 of 2) We will generate autologous (or syngeneic) or allogeneic LMP2A-specific cytotoxic T-cells and adoptively transfer them to patients with relapsed EBV-positive Hodgkin's or non-Hodgkins Lymphoma or …
Baylor Role: Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role: Lead Sponsor
Completed
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
The investigators will take 60-70 ml (12 teaspoonfuls) of blood from the patient to make a B cell line called a lymphoblastoid cell line or LCL by infecting the blood …
Baylor Role: Lead Sponsor